This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shih, I.-M. Articles by Kurman, R. J. Search for Related Content PubMed PubMed Citation Articles by Shih, I.-M. Articles by Kurman, R. J.

Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges

Authors' Affiliation: Departments of Pathology, Oncology, and Gynecology/Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland

Requests for reprints: Ie-Ming Shih, Johns Hopkins Medical Institutions, 1503 East Jefferson Street, Room B-315, Baltimore, MD 21231. Phone: 410-502-7774; Fax: 410-502-7943; E-mail: ishih{at}jhmi.edu.

Ovarian borderline (low malignant potential) tumors are a puzzling group of neoplasms that do not fall neatly into benign or malignant categories. Their behavior is enigmatic, their pathogenesis unclear, and their clinical management controversial, especially for serous borderline tumors (SBT), the most common type of ovarian borderline tumor. Clarifying the nature of borderline tumors and their relationship to invasive carcinoma has puzzled investigators since the category was created over 30 years ago. Much of the confusion and controversy concerning these tumors is due to a lack of understanding of their pathogenesis and an absence of a model for the development of ovarian carcinoma. This review summarizes recent molecular studies of ovarian borderline tumors with special emphasis on the role of SBT in tumor progression and its relationship to ovarian serous carcinoma.

This article has been cited by other articles:

				K.-T. Kuo, B. Guan, Y. Feng, T.-L. Mao, X. Chen, N. Jinawath, Y. Wang, R. J. Kurman, I.-M. Shih, and T.-L. Wang Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas Cancer Res., May 1, 2009; 69(9): 4036 - 4042. [Abstract] [Full Text] [PDF]

				A. Berchuck, E. S. Iversen, J. Luo, J. P. Clarke, H. Horne, D. A. Levine, J. Boyd, M. A. Alonso, A. A. Secord, M. Q. Bernardini, et al. Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome Clin. Cancer Res., April 1, 2009; 15(7): 2448 - 2455. [Abstract] [Full Text] [PDF]

				K. Levanon, C. Crum, and R. Drapkin New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact J. Clin. Oncol., November 10, 2008; 26(32): 5284 - 5293. [Abstract] [Full Text] [PDF]

				T.-V. Do, L. A. Kubba, M. Antenos, A. W. Rademaker, C. D. Sturgis, and T. K. Woodruff The Role of Activin A and Akt/GSK Signaling in Ovarian Tumor Biology Endocrinology, August 1, 2008; 149(8): 3809 - 3816. [Abstract] [Full Text] [PDF]

				G. Castellano, J. F. Reid, P. Alberti, M. L. Carcangiu, A. Tomassetti, and S. Canevari New Potential Ligand-Receptor Signaling Loops in Ovarian Cancer Identified in Multiple Gene Expression Studies Cancer Res., November 15, 2006; 66(22): 10709 - 10719. [Abstract] [Full Text] [PDF]